Company intelligence / Profile preview
Shanghai De Novo Pharmatech
Shanghai, Shanghai, Chinadenovo-sh.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
The company has two leading innate immune agonists in clinical stage: DN1508052 (TLR8 agonist) in Phase 1 in US and China, and DN015089 (STING agonist) in Phase 1 in China. Both candidates have potential as monotherapy and in combination with immune checkpoint inhibitors.
- Therapeutic areas
- Metabolic DisordersOncologyEndocrinologyInfectious Diseases
- Modalities
- Small moleculesimmune agonists
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →Beyond the preview
Go deeper on Shanghai De Novo Pharmatech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shanghai De Novo Pharmatech.